{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T17:02:41Z","timestamp":1790874161703,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.clml.2026.08.002","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T23:40:14Z","timestamp":1786146014000},"page":"670-688.e2","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["In Search of Long-Term Disease Control: CAR T-Cell Therapy With Axicabtagene Ciloleucel or Allogeneic Hematopoietic Cell Transplantation Against Relapsed\/Refractory Large B-Cell Lymphoma"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-7585-8956","authenticated-orcid":false,"given":"Markus","family":"Maulhardt","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-4850-7359","authenticated-orcid":false,"given":"Lina J.","family":"Kolloch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gina","family":"Westhofen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enver","family":"Aydilek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-7371-9013","authenticated-orcid":false,"given":"Margarete E.","family":"Laage","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Plate","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"B\u00fcntzel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexander C.","family":"Angleitner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9509-9036","authenticated-orcid":false,"given":"Kristian","family":"Thomson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfram","family":"Jung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Justin","family":"Hasenkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgenii","family":"Shumilov","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald G.","family":"Wulf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2026.08.002_bib0001","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.clml.2026.08.002_bib0002","doi-asserted-by":"crossref","first-page":"1720","DOI":"10.1038\/s41375-022-01620-2","article-title":"The 5th edition of the World Health Organization Classification of haematolymphoid tumours: lymphoid neoplasms","volume":"36","author":"Alaggio","year":"2022","journal-title":"Leukemia"},{"key":"10.1016\/j.clml.2026.08.002_bib0003","doi-asserted-by":"crossref","DOI":"10.1177\/20406207221103321","article-title":"Current options and future perspectives in the treatment of patients with relapsed\/refractory diffuse large B-cell lymphoma","volume":"13","author":"Frontzek","year":"2022","journal-title":"Ther Adv Hematol"},{"key":"10.1016\/j.clml.2026.08.002_bib0004","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.08.002_bib0005","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.08.002_bib0006","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1056\/NEJMoa1804980","article-title":"Tisagenlecleucel in adult relapsed or refractory diffuse large B-cell lymphoma","volume":"380","author":"Schuster","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.08.002_bib0007","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(20)31366-0","article-title":"Lisocabtagene maraleucel for patients with relapsed or refractory large B-cell lymphomas (TRANSCEND NHL 001): a multicentre seamless design study","volume":"396","author":"Abramson","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clml.2026.08.002_bib0008","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1056\/NEJMoa2116133","article-title":"Axicabtagene ciloleucel as second-line therapy for large B-cell lymphoma","volume":"386","author":"Locke","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.08.002_bib0009","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1182\/blood.2022018730","article-title":"Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study","volume":"141","author":"Abramson","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.08.002_bib0010","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/bmt.2013.72","article-title":"Allogeneic hematopoietic cell transplantation for diffuse large B cell lymphoma: who, when and how?","volume":"49","author":"Klyuchnikov","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2026.08.002_bib0011","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1111\/bjh.14046","article-title":"Allogeneic transplantation provides durable remission in a subset of DLBCL patients relapsing after autologous transplantation","volume":"174","author":"Fenske","year":"2016","journal-title":"Br J Haematol"},{"key":"10.1016\/j.clml.2026.08.002_bib0012","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1038\/s41409-021-01264-3","article-title":"Allogeneic stem cell transplantation as a curative option in relapse\/refractory diffuse large B cell lymphoma: spanish multicenter GETH\/GELTAMO study","volume":"56","author":"Bento","year":"2021","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2026.08.002_bib0013","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/s41409-019-0650-x","volume":"55","author":"Gonz\u00e1lez-Barca","year":"2020","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2026.08.002_bib0014","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1200\/JCO.2010.30.2596","article-title":"Allogeneic stem-cell transplantation as salvage therapy for patients with diffuse large B-cell non-Hodgkin\u2019s lymphoma relapsing after an autologous stem-cell transplantation: an analysis of the European Group for Blood and Marrow Transplantation Registry","volume":"29","author":"van Kampen","year":"2011","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.clml.2026.08.002_bib0015","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1056\/NEJMoa2301665","article-title":"Survival with axicabtagene ciloleucel in large B-cell lymphoma","volume":"389","author":"Westin","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.08.002_bib0016","doi-asserted-by":"crossref","DOI":"10.1016\/S2352-3026(23)00307-1","article-title":"CD19-directed CAR T cells as first salvage therapy for large B-cell lymphoma: towards a rational approach","volume":"10","author":"Dreger","year":"2023","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.clml.2026.08.002_bib0017","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.08.002_bib0018","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","article-title":"Long-term outcomes following CAR T cell therapy: what we know so far","volume":"20","author":"Cappell","year":"2023","journal-title":"Nat Rev Clin Oncol"},{"key":"10.1016\/j.clml.2026.08.002_bib0019","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"& Lymphoma Program investigators at the University of Pennsylvania. Five-year outcomes for refractory B-cell lymphomas with CAR T-cell therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.08.002_bib0020","doi-asserted-by":"crossref","first-page":"3581","DOI":"10.1200\/JCO.23.02786","article-title":"Five-year follow-up of standard-of-care axicabtagene ciloleucel for large B-cell lymphoma: results from the US lymphoma CAR T consortium","volume":"42","author":"Jain","year":"2024","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.clml.2026.08.002_bib0021","doi-asserted-by":"crossref","first-page":"e77","DOI":"10.1016\/j.bbmt.2019.12.771","article-title":"Cellular immunotherapy for refractory diffuse large B cell lymphoma in the chimeric antigen receptor-engineered T cell era: still a role for allogeneic transplantation?","volume":"26","author":"Dreger","year":"2020","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2026.08.002_bib0022","doi-asserted-by":"crossref","first-page":"898.e1","DOI":"10.1016\/j.jtct.2025.08.008","article-title":"Treatment of diffuse large B-cell lymphoma progressing or relapsing after chimeric antigen receptor T-cell therapy","volume":"31","author":"Kharfan-Dabaja","year":"2025","journal-title":"Transplant Cell Ther"},{"key":"10.1016\/j.clml.2026.08.002_bib0023","doi-asserted-by":"crossref","first-page":"98","DOI":"10.3324\/haematol.2022.281242","article-title":"Allogeneic transplant following CAR T-cell therapy for large B-cell lymphoma","volume":"108","author":"Zurko","year":"2023","journal-title":"Haematologica"},{"key":"10.1016\/j.clml.2026.08.002_bib0024","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1056\/NEJMoa2116596","article-title":"Second-line Tisagenlecleucel or Standard Care in aggressive B-cell lymphoma","volume":"386","author":"Bishop","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clml.2026.08.002_bib0025","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1016\/S0140-6736(22)00662-6","volume":"399","author":"Kamdar","year":"2022","journal-title":"Lancet Lond Engl"},{"key":"10.1016\/j.clml.2026.08.002_bib0026","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S1470-2045(14)70161-5","article-title":"Rituximab after lymphoma-directed conditioning and allogeneic stem-cell transplantation for relapsed and refractory aggressive non-Hodgkin lymphoma (DSHNHL R3): an open-label, randomised, phase 2 trial","volume":"15","author":"Glass","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clml.2026.08.002_bib0027","doi-asserted-by":"crossref","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"10.1016\/j.clml.2026.08.002_bib0028","series-title":"Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0","year":"2017"},{"key":"10.1016\/j.clml.2026.08.002_bib0029","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2026.08.002_bib0030","first-page":"825","article-title":"1994 Consensus Conference on acute GVHD grading","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2026.08.002_bib0031","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/j.bbmt.2005.09.004","article-title":"National Institutes of Health consensus development project on criteria for clinical trials in chronic graft-versus-host disease: I. Diagnosis and staging working group report","volume":"11","author":"Filipovich","year":"2005","journal-title":"Biol Blood Marrow Transplant J Am Soc Blood Marrow Transplant"},{"key":"10.1016\/j.clml.2026.08.002_bib0032","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1080\/10428194.2024.2438805","article-title":"Allogeneic stem cell transplantation against aggressive lymphomas: graft-versus-lymphoma effects in peripheral T-cell lymphoma and diffuse large B-cell lymphoma after myeloablative conditioning","volume":"66","author":"Shumilov","year":"2025","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2026.08.002_bib0033","doi-asserted-by":"crossref","first-page":"5571","DOI":"10.1182\/bloodadvances.2025016778","article-title":"Comparative real-world outcomes of CD19-directed CAR T-cell therapies in large B-cell lymphoma","volume":"9","author":"Desch\u00eanes-Simard","year":"2025","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.08.002_bib0034","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1158\/1078-0432.CCR-22-3136","article-title":"Safety and efficacy of Axicabtagene Ciloleucel versus standard of care in patients 65 years of age or older with relapsed\/refractory large B-cell lymphoma","volume":"29","author":"Westin","year":"2023","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"key":"10.1016\/j.clml.2026.08.002_bib0035","doi-asserted-by":"crossref","first-page":"e54","DOI":"10.1002\/hem3.54","article-title":"Chimeric antigen receptor-T cell therapy shows similar efficacy and toxicity in patients with diffuse large B-cell lymphoma aged 70 and older compared to younger patients: a multicenter cohort study","volume":"8","author":"Berning","year":"2024","journal-title":"HemaSphere"},{"key":"10.1016\/j.clml.2026.08.002_bib0036","doi-asserted-by":"crossref","first-page":"6589","DOI":"10.1182\/bloodadvances.2023010624","article-title":"Nonrelapse mortality after CAR T-cell therapy for large B-cell lymphoma: a LYSA study from the DESCAR-T registry","volume":"7","author":"Lemoine","year":"2023","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.08.002_bib0037","doi-asserted-by":"crossref","first-page":"5607","DOI":"10.1182\/bloodadvances.2020003001","article-title":"Predictive factors of early progression after CAR T-cell therapy in relapsed\/refractory diffuse large B-cell lymphoma","volume":"4","author":"Vercellino","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.08.002_bib0038","first-page":"2307","article-title":"Five-year follow-up of ZUMA-1 supports the curative potential of axicabtagene ciloleucel in refractory large B-cell lymphoma","volume":"141","author":"Neelapu","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.clml.2026.08.002_bib0039","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1182\/bloodadvances.2021005788","article-title":"Allogeneic transplant and CAR-T therapy after autologous transplant failure in DLBCL: a noncomparative cohort analysis","volume":"6","author":"Hamadani","year":"2022","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.08.002_bib0040","doi-asserted-by":"crossref","first-page":"6157","DOI":"10.1182\/bloodadvances.2020003036","article-title":"CAR T cells or allogeneic transplantation as standard of care for advanced large B-cell lymphoma: an intent-to-treat comparison","volume":"4","author":"Dreger","year":"2020","journal-title":"Blood Adv"},{"key":"10.1016\/j.clml.2026.08.002_bib0041","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41409-023-01949-x","article-title":"Role of allogeneic hematopoietic cell transplant for relapsed\/refractory aggressive B-cell lymphomas in the CART era","volume":"58","author":"Mussetti","year":"2023","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.clml.2026.08.002_bib0042","doi-asserted-by":"crossref","first-page":"102028","DOI":"10.1016\/j.jcyt.2025.102028","article-title":"Outcomes of tisagenlecleucel versus allogeneic hematopoietic stem cell transplantation in relapsed or refractory large B-cell lymphoma","volume":"28","author":"Kim","year":"2026","journal-title":"Cytotherapy"},{"key":"10.1016\/j.clml.2026.08.002_bib0043","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1007\/s00277-024-05677-0","article-title":"Allogeneic stem cell transplantation and CAR-T in B-cell non-Hodgkin lymphoma: a two-center experience and review of the literature","volume":"103","author":"Mercadal","year":"2024","journal-title":"Ann Hematol"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002521?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265026002521?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:16:56Z","timestamp":1790871416000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265026002521"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":43,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2152265026002521"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2026.08.002","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In Search of Long-Term Disease Control: CAR T-Cell Therapy With Axicabtagene Ciloleucel or Allogeneic Hematopoietic Cell Transplantation Against Relapsed\/Refractory Large B-Cell Lymphoma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2026.08.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}